Enhancement of Cetuximab-Induced Antibody-Dependent Cellular Cytotoxicity (ADCC) With Lenalidomide in Advanced Solid Tumors: a Phase I/IB Study

Trial Profile

Enhancement of Cetuximab-Induced Antibody-Dependent Cellular Cytotoxicity (ADCC) With Lenalidomide in Advanced Solid Tumors: a Phase I/IB Study

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Cetuximab
  • Indications Carcinoma; Colorectal cancer; Head and neck cancer; Salivary gland cancer; Squamous cell cancer; Tongue cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Oct 2013 Status changed from recruiting to completed.
    • 23 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
    • 28 May 2013 Planned end date changed from 1 Dec 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top